Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Omzo's brand materials describe tirzepatide as offering "dual-hormone support that targets appetite, blood sugar, and metabolism for deeper, sustained progress." Clinical trials of tirzepatide (the active ingredient in Zepbound and Mounjaro) have shown substantial weight loss outcomes in studied populations, and some trials have shown greater average weight reduction with tirzepatide compared to semaglutide in head-to-head comparisons - though individual responses vary and neither medication is appropriate for all patients
It is a GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist
Neonates with CHF may also need medical management including PGE1 to keep the ductus arteriosus open
We'll review it at a short initial visit
US$ 28.86
US$ 26.84
US$ 26.27
